GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CRDF · Dec 31, 2025

Cardiff Oncology, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001193125-26-067464General Corporate
Capex intensity17thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

7.42% · OPTIONAL · VALID

Operating cash generation57thOwn-history percentile · N=14
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-6395.11% · OPTIONAL · VALID

Revenue growth30thOwn-history percentile · N=10
Evidence method

Yoy · gp.fundamentals.revenue

-13.18% · CORE · VALID

Operating margin64thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.operating_margin

-8256.32% · CORE · VALID

SBC intensity43thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

960.03% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesSelf-history eligible
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
15.00%
Current
7.42%
Delta
-7.58%
Cash Generation Increased
Previous
-9028.33%
Current
-6395.11%
Delta
2633.22%
Growth Increased
Previous
-27.27%
Current
-13.18%
Delta
14.10%
Profitability Increased
Previous
-9978.33%
Current
-8256.32%
Delta
1722.01%
Sbc Intensity Decreased
Previous
1153.33%
Current
960.03%
Delta
-193.30%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.